Elanco Animal Health Inc has disclosed a recent transaction involving its CEO, Jeffrey N. Simmons, who acquired deferred stock units. This move is significant as it underscores the company's strategy to align executive compensation with the company's performance and shareholder interests.

Company Overview

Elanco Animal Health Inc, identified by CIK 0001739104, operates in the pharmaceutical preparations industry (SIC 2834). The company is publicly traded on the New York Stock Exchange under the ticker symbol ELAN. Elanco focuses on providing innovative health solutions for pets and livestock, enhancing animal health and welfare.

What the Filing Says

According to the SEC filing dated October 6, 2026, Simmons acquired 127.6843 deferred stock units on October 2, 2026, at a price of $22.14 per share. Following this transaction, he owns a total of 25,499.2826 shares of the company. The filing notes, "Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent." This reflects a commitment to performance-based compensation practices.

Impact

This transaction may impact various stakeholders, including shareholders who are interested in how executive compensation aligns with company performance. By acquiring these units, Simmons is signaling confidence in the company's future, which may positively influence investor sentiment. Additionally, this move could encourage other companies within the pharmaceutical preparations sector to adopt similar compensation structures.

What's Next

The filing does not say what happens next.